Retatrutide, a triple antagonist, achieves record weight loss.

Published Date: 27 Jun 2023

Retatrutide, a molecule that acts as an agonist to the GLP-1, GIP, and glucagon receptors, was used in two early studies to treat people with type 2 diabetes and people without, and it was linked to weight loss never before seen.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Stem Cell Selection Unneeded for SSc Transplant Therapy?

2.

Lung Transplant for Lung Cancer: Promising, in Rare Cases

3.

Rural-urban disparities seen in cervical cancer

4.

Obesity linked to subsequent neoplasms in childhood cancer survivors

5.

New policy review highlights the importance of health-related quality of life in advanced cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot